About this trial
To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.
Eligibility criteria
Qualifiers
Healthy women,
Assigned female at birth,
18-70 years of age,
Body mass index <18 or ≥30 kg/m2,
Disqualifiers
Assigned male at birth,
Pregnancy,
Breastfeeding,
History of hormone replacement therapy, chemical menopause, or oophor-ectomy
Trial design
Treatments tested in this trial
- Placebo
- Gemtesa
Treatment groups
60 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov